Calamos Advisors LLC Veracyte, Inc. Transaction History

Calamos Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 03, 2022	SELL	$21.94 - $42.51 $471,161 - $912,902	-21,475 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$36.09 - $53.79 $775,032 - $1.16 Million	21,475 New	21,475 $884,000
Q2 2021 Jul 22, 2021	SELL	$32.94 - $56.62 $1.84 Million - $3.17 Million	-56,000 Closed	0 $0
Q1 2021 Apr 12, 2021	BUY	$44.47 - $81.38 $196,512 - $359,618	4,419 Added 8.57%	56,000 $3.01 Million
Q4 2020 Jan 27, 2021	SELL	$32.49 - $61.88 $35,251 - $67,139	-1,085 Reduced 2.06%	51,581 $2.52 Million
Q3 2020 Oct 26, 2020	BUY	$26.73 - $35.67 $1.41 Million - $1.88 Million	52,666 New	52,666 $1.71 Million
Q1 2020 Apr 28, 2020	SELL	$16.13 - $30.17 $407,605 - $762,395	-25,270 Closed	0 $0
Q4 2019 Jan 15, 2020	SELL	$20.78 - $29.99 $2.3 Million - $3.32 Million	-110,750 Reduced 81.42%	25,270 $705,000
Q3 2019 Oct 21, 2019	SELL	$23.87 - $30.93 $1.48 Million - $1.91 Million	-61,899 Reduced 31.27%	136,020 $3.26 Million
Q2 2019 Aug 07, 2019	BUY	$22.1 - $28.56 $4.37 Million - $5.65 Million	197,919 New	197,919 $5.64 Million

307

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Calamos Advisors LLC with notifications on news.